SRZN a Penny biotech LONG

Updated
SRZN has had good momentum. It has no revenues. Clinical trials but a lot of cash. SRZN has

advanced trials underway for a product to treat alcoholic hepatitis presumably settling it down

before it becomes irreversible cirrhosis (only for patients who are alcohol-free) and also useful

for liver metabolic disorders from a genetic basis.

SRZN has been trending up for a week with a bit of a pause in the middle of it. It picked up

60% of its price while breaking out through the anchored VWAP lines and the volume profile.

The far greater market is the former.

It is priced at 90 or more off it's all-time high of about $160. IF it picks up hype from the

last clinical trial getting a report and a calendared review by the, SRZN could reach for that

all time high. This is speculative and risky as are most biotechnology penny stocks. They are

trading news and potential not current net revenues. A small position with room in the stop

loss for the average range and volatility is best. This is a typical high risk higher potential

reward type of trade.




Trade active
One week chart was uploaded in error but does show the all-time high. Linked here
is the 15-minute version snapshot
Trade active
AI indicator suggests that price might be topping out later this morning. It has been
a good trade. looking to see if it reverses .

snapshot
Trade closed: target reached
Reversal arrived and closed in profit.
biotechnologybiotechstocksclinicalstudyfdaapprovalLABUOscillatorspennystockVolatilityVolumeXBI

Disclaimer